Evidence map›Paper›PMID 39560740›Full record

ArticleAnnals of hematology2024

Reappraising the prognostic relevance of cytogenetic risk in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

Shohei Mizuno, Hiroki Hosoi, Akiyoshi Takami, Takahito Kawata, Noriko Doki, Wataru Takeda, Masatsugu Tanaka, Tetsuya Nishida, Naoyuki Uchida, Yuta Hasegawa and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Shohei MizunoAichi Medical University, Nagakute, Japan.
Hiroki HosoiWakayama Medical University, Wakayama, Japan.
Akiyoshi TakamiAichi Medical University, Nagakute, Japan.
Takahito KawataHyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
Noriko DokiTokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Wataru TakedaNational Cancer Center Hospital, Tokyo, Japan.
Masatsugu TanakaKanagawa Cancer Center, Yokohama, Japan.
Tetsuya NishidaJapanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
Naoyuki UchidaToranomon Hospital, Tokyo, Japan.
Yuta HasegawaHokkaido University Hospital, Sapporo, Japan.
Masashi SawaAnjo Kosei Hospital, Anjo, Japan.
Shuichi OtaSapporo Hokuyu Hospital, Sapporo, Japan.
Makoto OnizukaTokai University School of Medicine, Isehara, Japan.
Hirohisa NakamaeOsaka Metropolitan University Hospital, Osaka, Japan.
Noboru AsadaOkayama University Hospital, Okayama, Japan.
Takahiro FukudaNational Cancer Center Hospital, Tokyo, Japan.
Makoto YoshimitsuGraduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Yoshinobu KandaJichi Medical University, Shimotsuke, Japan.
Marie OhbikiAichi Medical University, Nagakute, Japan.
Yoshiko AtsutaAichi Medical University, Nagakute, Japan.
Takaaki KonumaThe Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Masamitsu YanadaNagoya City University East Medical Center, Nagoya, Japan. myanada@med.nagoya-cu.ac.jp.

Funding

Japan Agency for Medical Research and Development 19ek0510023h0003Japan Society for the Promotion of Science JP24K11566
6 · The paper itself

Abstract

This study aimed to investigate the prognostic relevance of cytogenetic risk in 9826 adults with acute myeloid leukemia (AML) who underwent allogeneic hematopoietic cell transplantation (HCT) during the first or second complete remission. The 5-year probabilities of overall survival (OS) were 66%, 61%, and 47% (P < 0.001), the cumulative incidences of relapse were 14%, 19%, and 32% (P < 0.001), and the cumulative incidences of non-relapse mortality (NRM) were 23%, 23%, and 25% (P = 0.208) in patients with favorable (n = 1418), intermediate (n = 6747), and poor cytogenetic risk (n = 1661), respectively. The significant effect of cytogenetic risk on OS was strong in all subgroups stratified by age, sex, performance status, disease status, donor type, conditioning intensity, graft-versus-host disease prophylaxis, and transplantation period (P < 0.001 for all). The evaluation of trends in posttransplant outcomes for patients in each cytogenetic risk category indicated that the risk of relapse declined in patients with favorable and intermediate cytogenetics and that the risk of NRM decreased in those with intermediate and poor cytogenetics. Therefore, patients with intermediate cytogenetics experienced the best OS improvement. These results confirm cytogenetic risk as a universal prognostic factor in patients with AML undergoing allogeneic HCT while highlighting the requirement for further improvements in posttransplant OS by reducing NRM in patients with favorable cytogenetics and by reducing relapse in patients with poor cytogenetics.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAdolescentAdultAgedAllograftsChromosome AberrationsFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsSurvival RateTransplantation ConditioningAcute myeloid leukemiaAllogeneic hematopoietic cell transplantationCytogeneticsPrognosis

Identifiers

PMID39560740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.